Annexure-A

## Dividend Distribution Compliance Report

Under Clause (6) of the Directive No. BSEC/CM RRCD/2021-386/03, Dated: 14/01/2021

1	Name of the Issuer/Securities/Mutual Fund	Square Pharmaceuticals Ltd.			
2	Particulars of Issuer DP	Square Securities Management Ltd. TREC # 76			
3	Type of Dividend (Annual/Interim)	a) Annual 🚺 b) Interim			
	(Put tick mark ( $v$ ) on the recommended option)				
4	Whether audited or not for Interim Dividend	a) Audited b) Unaudited			
	(Put tick mark ( $v$ ) on the recommended option)				
5	Date of recommendation of Dividend by the Board of Directors/Trustee:	20-10-2022			
	(Enclose copy of PSI)	PSI enclosed (A)			
6	Whether Dividend recommended other than directors or sponsors or any other classes	a) Yes 🔲 b) No 🔽			
	(Put tick mark (V) on the recommended option)				
7	Record date for entitlement	28-11-2022			
8	Rate of Dividend recommended by the Board of Directors/Trustee	100%			
9	Dividend recommended -Type	a) Cash 🗸 b) Stock			
10	(Put tick mark (v) on the recommended option)				
	Securities/mutual fund traded under which categories	a) A b) B	c) C d) D	e) Z	
	(Put tick mark ( $\nu$ ) on the recommended option)				
11	Date of transfer to a separate bank account (PIs. mention bank details)	27-10-2022			
	or provisional credit of shares/units by CDBL	Standard Chartered Bank, A/c # 01607874503			
12	Date of approval of Dividend at AGM	24-12-2022			
13	Rate of Dividend approved at AGM -details at Annexure, (if any change)	100% (Cash)			
14	Date of commencement of disbursement of Cash and Stock Dividend	10-01-2023			
15	Mode of disbursement of Cash Dividend	a) BEFTN 🚺 b) Bank Transfer 🚺 c) MFS 🛄			
	(Put tick mark (V) on the recommended option)	d) Dividend Warrant 🔽 e) Any other Mode 🗌			
16	Date of completion of disbursement of Cash Dividend and Stock Dividend	23	23-01-2023 Enclosed Bank Statement (B)		
	[Enclose Bank statements and Corporate Action Processing Report (DP 70)]	Enclosed E			
17	Paid-up-capital of the Issuer- before corporate action/entitlement Tk.	8,864,510,100.00			
18	Numbers of securities/shares outstanding- before corporate action/entitlement:	886,451,010			
19	Total Cash in taka or Stock (nos. shares) dividend as per corporate declaration	Cash:	8,864,510,100.00 (in Taka)		
		Stock :	-		
20	Distribution/Disbursement details of Cash & Stock Dividend:	Cash (Tk.)	Stock (Nos.)	Annexure	
	A. Mode of Dividend payment/credit for the concerned year:	8,864,510,100.00			
	a) through BEFTN or directly credited to respective BO	8,568,580,456.00	-		
	b) through Bank Transfer other than entitled BO-Margin loan	-	-		
	c) through Bank Transfer	-	-		
	d) through Mobile Financial Service (MFS)	-	-		
	e) through any other mode as approved by Bangladesh Bank	-	-		
	f) through transfer to Suspense Account for demate rialized Shares				
	(BO wise detailed with reason should be maintained and submitted )		-		
	g) through issuance of Dividend Warrant or issue of shares to	295,929,644.00 -			
	Suspense Account for non-dematerialized securities				
21	Total Dividend paid/credited for the concerned year	8,864,510,100.00	-		
22	Total unpaid/undistributed Dividend/accrued during the period (21-22)	-	-		



Dividend Distribution Compliance Report 1 of

Square Pharmaceuticals Ltd.

			Anr	nexure-A	
23	Total unpaid/undistributed Dividend /accrued as on 1st day of Accounting year (as per Audited Accounts)	. 129,636,029.00	-		
24	Transfer to Suspense Account for Demate Shares or any other reasons during the concerned year	23,947,432.80			
	A. Mode of Dividend Receipts/payment/credit for the previous years:				
	a) through BEFTN or directly credited to respective BO	-			
	b) through Bank Transfer	-			
	c) through Mobile Financial Service (MFS)	- 1	-		
	d) through any other mode as approved by Bangladesh Bank	-	-		
	e) through transfer to/from Suspense Account for Demate Shares or any other reasons	-	· • .		
	<ul> <li>f) through issuance of Dividend Warrant or issue of shares to Suspense Account for non-dematerialized securities/shares/units</li> </ul>	-	-		
	g) transfer of cash or stocks to the Fund as prescribed or directed by Commission after 3 years or forfeit of share lo Suspense Account for non-dematerialized securities	23,947,432.80	-		
25	Total Dividend paid/credited for previous years:	27,753,784.93	4 -		
26	Total unpaid/undistributed Dividend for previous years (23+24-25) Taka/Nos	125,829,676.87	-		
27	Grand Total of unpaid/undistributed Dividend (22+26)	125,829,676.87	-		
	Aging of grand Total of unnaid/undistributed Dividend for previous years:				
	More than 3 years; balance	-	-		
28	More than 4 years; balance	-	-		
	More than 5 years & above; balance	-	-		
	Total of unpaid/undistributed Dividend for previous years	125,829,676.87	-		
	(Supporting bank statements and balances of securities with the Depository)	Enclosed Bank Stat	tatement (C)		

Note: Issuer shall maintain BO wise detailed information for all transfers/credit to suspended Accounts with reasons and submit along with bank statements and other supporting documents. The issuer shall fill up all the applicable fields.



Square Pharmaceuticals Ltd.

Dividend Distribution Compliance Report 2 of .